Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Skadden said it published its inaugural report on Hong Kong-listed Specialist Technology Companies under the Chapter 18C listing regime. The firm said the report examined market data and corporate governance for 27 companies listed by September 30, 2026, across the eligible technology and new economy sectors.
Skadden said it published an article on how FDA regulatory reform, the maturing biosimilar patent framework and coming patent expirations are reshaping biosimilars M&A. The firm said FDA draft guidance since October 2025 lets sponsors replace comparative efficacy studies with analytical and pharmacokinetic data, that 118 biologics are expected to lose protection between 2025 and 2034, and that licensing remains the most common deal structure alongside acquisitions.